Ajanta Pharma Limited (AJANTPHARM) - Total Liabilities
Based on the latest financial reports, Ajanta Pharma Limited (AJANTPHARM) has total liabilities worth Rs13.57 Billion INR (≈ $146.80 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Ajanta Pharma Limited annual equity growth to track the company's year-over-year net asset growth rate.
Ajanta Pharma Limited - Total Liabilities Trend (2005–2025)
This chart illustrates how Ajanta Pharma Limited's total liabilities have evolved over time, based on quarterly financial data. See AJANTPHARM FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Ajanta Pharma Limited Competitors by Total Liabilities
The table below lists competitors of Ajanta Pharma Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Resideo Technologies Inc
NYSE:REZI
|
USA | $5.29 Billion |
|
Dyno Nobel Ltd
AU:DNL
|
Australia | AU$2.95 Billion |
|
Sichuan Changhong Electric Co Ltd
SHG:600839
|
China | CN¥73.26 Billion |
|
Guoyuan Securities Co Ltd
SHE:000728
|
China | CN¥147.32 Billion |
|
Faw Car Co Ltd
SHE:000800
|
China | CN¥55.95 Billion |
|
Hyundai Motor Co Pref
KO:005387
|
Korea | ₩229.09 Trillion |
|
Icahn Enterprises LP
NASDAQ:IEP
|
USA | $11.41 Billion |
|
RTL GROUP UNSP.ADR 10
F:RRTU
|
Germany | €4.97 Billion |
Liability Composition Analysis (2005–2025)
This chart breaks down Ajanta Pharma Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of Ajanta Pharma Limited.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.93 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.00 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.31 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.24 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Ajanta Pharma Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Ajanta Pharma Limited (2005–2025)
The table below shows the annual total liabilities of Ajanta Pharma Limited from 2005 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | Rs12.25 Billion ≈ $132.44 Million |
+14.34% |
| 2024-03-31 | Rs10.71 Billion ≈ $115.83 Million |
-17.04% |
| 2023-03-31 | Rs12.91 Billion ≈ $139.62 Million |
+63.17% |
| 2022-03-31 | Rs7.91 Billion ≈ $85.57 Million |
+1.04% |
| 2021-03-31 | Rs7.83 Billion ≈ $84.69 Million |
+8.79% |
| 2020-03-31 | Rs7.20 Billion ≈ $77.85 Million |
+59.62% |
| 2019-03-31 | Rs4.51 Billion ≈ $48.77 Million |
+10.74% |
| 2018-03-31 | Rs4.07 Billion ≈ $44.04 Million |
+59.68% |
| 2017-03-31 | Rs2.55 Billion ≈ $27.58 Million |
-17.57% |
| 2016-03-31 | Rs3.09 Billion ≈ $33.46 Million |
+1.35% |
| 2015-03-31 | Rs3.05 Billion ≈ $33.01 Million |
-14.26% |
| 2014-03-31 | Rs3.56 Billion ≈ $38.50 Million |
+9.51% |
| 2013-03-31 | Rs3.25 Billion ≈ $35.16 Million |
-7.32% |
| 2012-03-31 | Rs3.51 Billion ≈ $37.94 Million |
+19.58% |
| 2011-03-31 | Rs2.93 Billion ≈ $31.72 Million |
-5.43% |
| 2010-03-31 | Rs3.10 Billion ≈ $33.54 Million |
+1.44% |
| 2009-03-31 | Rs3.06 Billion ≈ $33.07 Million |
+36.04% |
| 2008-03-31 | Rs2.25 Billion ≈ $24.31 Million |
+47.15% |
| 2007-03-31 | Rs1.53 Billion ≈ $16.52 Million |
+15.49% |
| 2006-03-31 | Rs1.32 Billion ≈ $14.30 Million |
+11.06% |
| 2005-03-31 | Rs1.19 Billion ≈ $12.88 Million |
-- |
About Ajanta Pharma Limited
Ajanta Pharma Limited, together with its subsidiaries, a pharmaceutical formulation company that develops, manufactures, and markets specialty pharmaceutical finished dosages. The company offers chronic and acute therapies; branded generic products; and a range of dosage forms, including tablets, capsules, injectables, inhalers, ointments, creams, and liquids. It also serves various therapeutic a… Read more